Cargando…
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fi...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382860/ https://www.ncbi.nlm.nih.gov/pubmed/22737619 http://dx.doi.org/10.4161/onci.18963 |